Biomarker Alteration to Neoadjuvant Chemotherapy Predict Pathological Response and Prognosis in Breast Cancer Patients
Dongwei Zhang2, 3
1 Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
2 Department of Surgery, the Second Affiliated of Harbin Medical University, Harbin, Heilongjiang, China
3 Heilongjiang Academy of Medical Sciences, Harbin, Heilongjiang, China
Cancer Genetics and Epigenetics, 2018, Vol. 6, No. 1 doi: 10.5376/cge.2018.06.0001
Received: 29 Mar., 2018 Accepted: 09 Apr., 2018 Published: 18 May, 2018
© 2018 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Zhao Y., and Zhang D.W., 2018, Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients, Cancer Genetics and Epigenetics, 6(1): 1-12 (doi: 10.5376/cge.2018.06.0001)
Background: The values of biomarkers expression might be changed following neoadjuvant chemotherapy (NACT), but little is known about the change range and its relationship to prognosis. This study aimed to investigate the potential changes of biomarkers expression before and after neoadjuvant chemotherapy, then predicting the pathological response and prognosis to NACT. Methods: A total of 119 patients who were initially diagnosed of breast cancer and underwent neoadjuvant chemotherapy were included in the study. Miller-Payne grading system was used to evaluate the pathologic response after neoadjuvant chemotherapy. Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was used to test for differences between groups. Results: The high expression of ER, PR and Ki67 pre-NACT, the biomarkers expression post-NACT is also high (All P values <0.05). We found that the change of biomarkers expression before and after chemotherapy were all considered as medium changes (range between 10 to 30), while only PR expression change after NACT were associated with distant disease-free survival (P<0.001) and overall survival (P=0.031,6). PR expression also related to pathologic response (P=0.028) but not ER, HER2 and Ki-67. Furthermore, a total of 67 down regulated of Ki67 expression compared with 37 up regulated expression, the results showed that decreasing expression of Ki67 had fewer local recurrence compared with Ki67 increasing expression after NACT. Conclusions: Our research have provided the prognostic value of biomarkers expression change following the neoadjuvant chemotherapy. These findings might help optimize the choice of targeted therapy and improve the predictive effect to patient survival.
Breast cancer; Neoadjuvant chemotherapy; Biomarkers; Expression; Prognosis
Cancer Genetics and Epigenetics
• Volume 6